mhurhangee/patent-ind-claim-en huggingface dataset:
An on-chip microwave filter circuit comprising: a substrate formed of a first material that exhibits a first threshold level of thermal conductivity, wherein the first threshold level of thermal conductivity is achieved at a cryogenic temperature range in which a quantum computing circuit operates; and a dispersive component configured to filter a plurality of frequencies in an input signal, the dispersive component comprising a first transmission line disposed on the substrate and a second transmission line disposed on the substrate; a first connector coupled to the first transmission line; a second connector coupled to the second transmission line; and, a housing coupled to the substrate; wherein the first and second transmission lines, the first and second connectors, and the housing, are all formed of a second material that exhibits a second threshold level of thermal conductivity, wherein the second threshold level of thermal conductivity is achieved at a cryogenic temperature range in which a quantum computing circuit operates. a substrate formed of a first material that exhibits a first threshold level of thermal conductivity, wherein the first threshold level of thermal conductivity is achieved at a cryogenic temperature range in which a quantum computing circuit operates; and a dispersive component configured to filter a plurality of frequencies in an input signal, the dispersive component comprising a first transmission line disposed on the substrate and a second transmission line disposed on the substrate; a first connector coupled to the first transmission line; a second connector coupled to the second transmission line; and, a housing coupled to the substrate; wherein the first and second transmission lines, the first and second connectors, and the housing, are all formed of a second material that exhibits a second threshold level of thermal conductivity, wherein the second threshold level of thermal conductivity is achieved at a cryogenic temperature range in which a quantum computing circuit operates.
Lens with an extended range of focus, wherein the lens consists of a transparent material and has a first manufactured optical surface and a second manufactured optical surface , wherein the lens has a optical power distribution F Ges , characterized in that the optical power distribution F Ges of the lens , in relation to a plane perpendicular to the optical axis , changes as a function of the radial height (r) and of the azimuth angle (phi) of the aperture between a calculated basic value of the optical power F Linse not equal to zero and a maximum value F Spirale max (r, phi), and hence the optical power distribution emerges by calculation as F Ges (r, phi) = F Linse (r) + F Spirale max (r, phi) *w(phi) , where F Spirale max (r, phi) depends nonlinearly on the radius and is unequal to zero and w(phi) is a factor for the optical power component with the spiral profile, wherein phi takes values between 0 and 2n and w(phi) takes values greater than or equal to zero and less than or equal to one, and in that the calculated basic value of the optical power F Linse is split into a refractive optical power component of a base system F Basis and into a optical power component of a structure F Struktur unequal to zero, where the structure is a height profile of a Fresnel lens or a phase profile of a diffractive optical element, DOE, or a refractive index gradient of a gradient index lens, GRIN lens, furthermore a spiral optical power component F Spirale ( r, phi) = F Spirale max (r, phi) *w (phi) and the optical power component of the structure F Struktur being combined to form a spiral and structure-shaped additional optical power F SS (r, phi) = F Struktur + F Spirale ( r, phi) such that the overall optical power of the manufactured lens emerges as F Ges r phi = F Basis + F ss r phi .
Continuously operating press for producing wood-based or plastic boards, in particular fiberboards or chipboards, having a plurality of press frames which are arranged one behind the other in the longitudinal direction of the press and each have upper yokes and lower yokes and surround heating plates which extend in the longitudinal direction of the press, and having flexible endless steel belts which draw the material to be pressed through the press, are guided around the plurality of upper yokes and lower yokes via drive drums and deflection rollers, and which are supported against the heating plates via co-rotating supporting elements which are guided with their axles transversely to the belt running direction and roll along with them, 16), wherein the press gap disposed between the steel belts is adjustable via a plurality of hydraulic cylinders arranged next to one another between the upper yokes and the upper heating plate transversely to the belt running direction , and wherein the lower heating plates are supported against the pressure applied to the lower yokes by the hydraulic cylinders , characterized in that the press frames each consist of upper yokes and lower yokes connected to one another by tie rods , wherein the lower yokes are each formed by two parallel plates which are arranged on both sides in each case outside the tie rods .
A method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein said porous support comprises cross-linked agarose particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers, and a dry solids weight of 55-80 mg/ml and a pore size corresponding to an inverse gel filtration chromatography Kd value of 0.69-0.85 for dextran of Mw 110 kDa, and wherein said separation matrix has a max pressure of at least 0.58, such as at least 0.60, MPa when packed at 300 +/-10 mm bed height in a FineLineTM 35 column, b) contacting a liquid sample comprising an immunoglobulin with said separation matrix, wherein at least 40 mg immunoglobulin per ml separation matrix is contacted with said separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein said alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine, such as to a glutamic acid. a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein said porous support comprises cross-linked agarose particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers, and a dry solids weight of 55-80 mg/ml and a pore size corresponding to an inverse gel filtration chromatography Kd value of 0.69-0.85 for dextran of Mw 110 kDa, and wherein said separation matrix has a max pressure of at least 0.58, such as at least 0.60, MPa when packed at 300 +/-10 mm bed height in a FineLineTM 35 column, b) contacting a liquid sample comprising an immunoglobulin with said separation matrix, wherein at least 40 mg immunoglobulin per ml separation matrix is contacted with said separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid,
A valve for a drain channel of a sanitary appliance, comprising: a flexible tubular structure extending between an inlet end defining an inlet opening for receiving fluid into an interior of the tubular structure, and an outlet end downstream of the inlet opening, the tubular structure defining a flow direction (f), wherein the tubular structure is adapted to deform from - a closed state, in absence of fluid applying a pressure to the interior of the tubular structure, in which the outlet end is closed, to - an open state, in response to a pressure of fluid applied to the interior of the tubular structure, in which the outlet end is open, defining an outlet opening; characterised in that the outlet end has a V-shaped cross-section across the flow direction when the tubular structure is in the closed state. a flexible tubular structure extending between an inlet end defining an inlet opening for receiving fluid into an interior of the tubular structure, and an outlet end downstream of the inlet opening, the tubular structure defining a flow direction (f), wherein the tubular structure is adapted to deform from - a closed state, in absence of fluid applying a pressure to the interior of the tubular structure, in which the outlet end is closed, to - an open state, in response to a pressure of fluid applied to the interior of the tubular structure, in which the outlet end is open, defining an outlet opening; - a closed state, in absence of fluid applying a pressure to the interior of the tubular structure, in which the outlet end is closed, to - an open state, in response to a pressure of fluid applied to the interior of the tubular structure, in which the outlet end is open, defining an outlet opening; characterised in that the outlet end has a V-shaped cross-section across the flow direction when the tubular structure is in the closed state.
Pharmaceutical composition comprising or consisting of a) isolated whole blood cells and / or Peripheral Blood Mononuclear Cells (PBMCs) treated with a therapeutically effective amount of an active substance, and b) optionally a pharmaceutically acceptable carrier, for use in the prevention and / or treatment of organ or cell graft rejection in a human graft recipient, wherein the isolated whole blood cells or PBMCs are obtained or derived from the graft donor, wherein the prevention and / or treatment of organ or cell graft rejection comprises administering the pharmaceutical composition to the recipient, wherein the amount of the pharmaceutical composition is selected such that at least 1.5 × 10 6 cells of the treated whole blood cells or the treated PBMCs per kg body weight of the recipient are administered, preferably in one administration step, wherein the prevention and / or treatment of organ or cell graft rejection comprises administering to the recipient at least 1 × 10 8 cells of the treated whole blood cells or the treated PBMCs per kg body weight of the recipient, wherein the administration is performed at least 5 days before the transplantation, wherein the active substance comprises or consists of one or more substances selected from the group consisting of chemotherapeutics, proteasome inhibitors, immunosuppressive agents, anti-proliferative substances and combinations thereof. a) isolated whole blood cells and / or Peripheral Blood Mononuclear Cells (PBMCs) treated with a therapeutically effective amount of an active substance, and b) optionally a pharmaceutically acceptable carrier, for use in the prevention and / or treatment of organ or cell graft rejection in a human graft recipient, wherein the isolated whole blood cells or PBMCs are obtained or derived from the graft donor, wherein the prevention and / or treatment of organ or cell graft rejection comprises administering the pharmaceutical composition to the recipient, wherein the amount of the pharmaceutical composition is selected such that at least 1.5 × 10 6 cells of the treated whole blood cells or the treated PBMCs per kg body weight of the recipient are administered, preferably in one administration step, wherein the prevention and / or treatment of organ or cell graft rejection comprises administering to the recipient at least 1 × 10 8 cells of the treated whole blood cells or the treated PBMCs per kg body weight of the recipient, wherein the administration is performed at least 5 days before the transplantation, wherein the active substance comprises or consists of one or more substances selected from the group consisting of chemotherapeutics, proteasome inhibitors, immunosuppressive agents, anti-proliferative substances and combinations thereof.
A portable device comprising: a touch screen configured to display a first screen and an application screen of an executed application; and a control unit configured to control the touch screen and to execute the application, and a storage unit, wherein the control unit is configured to, when the first screen is displayed, detect a number of touch gestures on a touch gesture length detection region of the first screen, calculate an average of the lengths of the number of touch gestures, calculate a ratio of the average to a maximum length of the number of touch gestures, and store the ratio as a first gesture setting in the storage unit, wherein the control unit is configured to, when the application screen is displayed, control presentation of the display of the application screen to move in correspondence to a direction of a continuous movement of a first touch that is detected on the application screen, and control a movement distance of the displayed application screen to be different than a movement distance of the detected first touch in accordance with the stored first gesture setting. a touch screen configured to display a first screen and an application screen of an executed application; and a control unit configured to control the touch screen and to execute the application, and a storage unit, wherein the control unit is configured to, when the first screen is displayed, detect a number of touch gestures on a touch gesture length detection region of the first screen, calculate an average of the lengths of the number of touch gestures, calculate a ratio of the average to a maximum length of the number of touch gestures, and store the ratio as a first gesture setting in the storage unit, wherein the control unit is configured to, when the application screen is displayed, control presentation of the display of the application screen to move in correspondence to a direction of a continuous movement of a first touch that is detected on the application screen, and control a movement distance of the displayed application screen to be different than a movement distance of the detected first touch in accordance with the stored first gesture setting.
A mobile three-way calling terminal for a mobile human-machine coordination calling robot, comprising: a first speech interface, configured be connected to a back-end processing module, and to transfer call audio between a call object and the back-end processing module, the call object representing a user for establishing call connection to the three-way calling terminal by using a user terminal, wherein the back-end processing module is configured to interact with the call object according to a present rule; a CODEC1 module, configured to encode and/or decode the call audio between the call object and the back-end processing module; a second speech interface, configured to be connected to a human agent, and transfer call audio between the human agent and the call object, wherein the second speech interface is further configured to transfer the call audio between the call object and the back-end processing module to the human agent; a CODEC2 module, configured to encode and/or decode the call audio between the human agent and the call object; a call control module, configured to process a control signal, and automatically make, answer, and hang up a call; a data processing submodule, configured to process speech data and perform data transfer between the data processing submodule and the back-end processing module; and a networking submodule, configured to perform network connection to the back-end processing module. a first speech interface, configured be connected to a back-end processing module, and to transfer call audio between a call object and the back-end processing module, the call object representing a user for establishing call connection to the three-way calling terminal by using a user terminal, wherein the back-end processing module is configured to interact with the call object according to a present rule; a CODEC1 module, configured to encode and/or decode the call audio between the call object and the back-end processing module; a second speech interface, configured to be connected to a human agent, and transfer call audio between the human agent and the call object, wherein the second speech interface is further configured to transfer the call audio between the call object and the back-end processing module to the human agent; a CODEC2 module, configured to encode and/or decode the call audio between the human agent and the call object; a call control module, configured to process a control signal, and automatically make, answer, and hang up a call; a data processing submodule, configured to process speech data and perform data transfer between the data processing submodule and the back-end processing module; and a networking submodule, configured to perform network connection to the back-end processing module.
A composition comprising a red clover extract, which has been fermented by one or more lactic acid bacteria species, wherein the composition comprises red clover isoflavones, and wherein at least 90% of the isoflavones are in an aglycone form.
A swirler assembly , comprising: a swirler body having a swirler inlet extending through the swirler body; a guide plate having a guide plate flange and a guide plate collar ; and a retaining ring ; the guide plate flange being configured for engagement with the swirler body; the guide plate collar having an aft protrusion with respect to an axial direction extending through the swirler body; the aft protrusion having an aft protrusion tip position configured to be equal to or extend downstream of a swirler inlet forward position with respect to the axial direction and a radially outer surface that forms a radially outer surface angle greater than ninety degrees with respect to a radial direction; wherein the swirler body has a retainer body ; characterised in that the retainer body includes an angled wall in axisymmetric cross section, the angled wall defining a retainer body angle with respect to a plane perpendicular to the axial direction; wherein the angled wall provides a non-rectangular shape of the retainer body in axisymmetric cross section, with the angled wall being non-perpendicular to the axial direction and positioned upstream of the swirler inlet; wherein the angled wall provides for a recirculation zone radially inward of the angled wall that extends radially inward of a radially inner face of the retainer body; wherein the recirculation zone is a region defined by an axial length of the radially inner face of the retainer body together with the length of the angled wall; and wherein the retainer body angle ranges from five degrees (5°) to eighty-five degrees (85°). a swirler body having a swirler inlet extending through the swirler body; a guide plate having a guide plate flange and a guide plate collar ; and a retaining ring ; the guide plate flange being configured for engagement with the swirler body; the guide plate collar having an aft protrusion with respect to an axial direction extending through the swirler body; the aft protrusion having an aft protrusion tip position configured to be equal to or extend downstream of a swirler inlet forward position with respect to the axial direction and a radially outer surface that forms a radially outer surface angle greater than ninety degrees with respect to a radial direction; wherein the swirler body has a retainer body ; characterised in that the retainer body includes an angled wall in axisymmetric cross section, the angled wall defining a retainer body angle with respect to a plane perpendicular to the axial direction; wherein the angled wall provides a non-rectangular shape of the retainer body in axisymmetric cross section, with the angled wall being non-perpendicular to the axial direction and positioned upstream of the swirler inlet; wherein the angled wall provides for a recirculation zone radially inward of the angled wall that extends radially inward of a radially inner face of the retainer body; wherein the recirculation zone is a region defined by an axial length of the radially inner face of the retainer body together with the length of the angled wall; and wherein the retainer body angle ranges from five degrees (5°) to eighty-five degrees (85°).
A plasticizer composition, comprising: 70 to 99 wt% of a first plasticizer comprising a terephthalate-based material and a citrate-based material; and 1 to 30 wt% of a second plasticizer comprising an epoxidized alkyl ester composition containing one or more kinds of a compound represented by Formula 1 below, wherein the terephthalate-based material is one or more selected from the group consisting of di(2-ethylhexyl) terephthalate (DEHTP) and diisononyl terephthalate (DINTP), the citrate-based material is one or more selected from the group consisting of tributyl citrate (TBC) and tripentyl citrate (TPC), and a weight ratio of the terephthalate-based material and the citrate-based material is 80:20 to 60:40: in Formula 1, R 1 is an alkyl group of 8 to 20 carbon atoms, containing one or more epoxy groups, and R 2 is an alkyl group of 4, 5, or 8 to 10 carbon atoms; wherein the epoxidized alkyl ester composition has an iodine value of less than 3.5 I 2 g/100 g. 70 to 99 wt% of a first plasticizer comprising a terephthalate-based material and a citrate-based material; and 1 to 30 wt% of a second plasticizer comprising an epoxidized alkyl ester composition containing one or more kinds of a compound represented by Formula 1 below, wherein the terephthalate-based material is one or more selected from the group consisting of di(2-ethylhexyl) terephthalate (DEHTP) and diisononyl terephthalate (DINTP), the citrate-based material is one or more selected from the group consisting of tributyl citrate (TBC) and tripentyl citrate (TPC), and a weight ratio of the terephthalate-based material and the citrate-based material is 80:20 to 60:40: in Formula 1, R 1 is an alkyl group of 8 to 20 carbon atoms, containing one or more epoxy groups, and R 2 is an alkyl group of 4, 5, or 8 to 10 carbon atoms; wherein the epoxidized alkyl ester composition has an iodine value of less than 3.5 I 2 g/100 g. R 1 is an alkyl group of 8 to 20 carbon atoms, containing one or more epoxy groups, and R 2 is an alkyl group of 4, 5, or 8 to 10 carbon atoms; wherein the epoxidized alkyl ester composition has an iodine value of less than 3.5 I 2 g/100 g.
A bicycle headlamp, comprising a lens , said lens having a focal point space (FL), a light source for emitting light beams, and a reflector for reflecting said light beams towards said lens , which reflector comprises a first reflecting area to reflect said light beams from said first reflecting area towards said lens substantially through said focal point space (FL), characterized in that said first reflecting area has a shape, which is substantially a part of an elongated spheroid with a first reflecting focal point space (FR1) and a second reflecting focal point space (FR2) and wherein the light source is positioned substantially in the first reflecting focal point space (FR1) and the focal point space (FL) of the lens and the second reflecting focal point space (FR2) substantially coincide and that said reflector further comprises a second reflecting area , which first and second reflecting areas have different shapes, and which second reflecting area has a form of a paraboloid or spheroid having a major axis that is longer than in the first reflecting area , for reflecting said light beams from said second reflecting area towards said lens through a fictional plane between the lens and the focal point space (FL) of the lens .